N-of-1 Trial¶

A prospective within-person experiment in which one participant receives comparative intervention conditions over multiple planned periods to estimate that individual's treatment response.

Version: v1 · 2026-09-28 · History
Domain-specific #: 10888
Domain group: Applied Sciences & Engineering
Origin domain: Medicine & Healthcare
Subdomains: Clinical Research, Individualized Crossover Trials → Medicine & Healthcare
Aliases: N=1 trial, Single-patient crossover trial, Individualized crossover trial

Core Idea¶

An N-of-1 trial brings controlled comparison inside one participant. Two or more treatment conditions are administered across multiple periods, commonly as repeated crossover pairs or blocks. Randomizing order, masking treatment identity, standardizing outcomes, and replicating periods reduce alternative explanations, although not every design can use every safeguard.

The design is most informative when the condition is sufficiently stable, outcomes respond repeatedly, treatment effects begin within a useful period, and carryover can wash out or be modeled. Its primary estimand concerns the participant, not an average patient. A prospectively planned series can combine several N-of-1 trials, but population inference then needs a hierarchical or other explicit aggregation model. CENT reporting guidance makes sequence, periods, washouts, outcomes, harms, protocol, and analysis visible.

Structural Signature¶

Sig role-phrases:

Single participant — Defines the primary unit of treatment comparison and inference. It is required unit. Counterfactual: Pooling people without within-person estimation is a group trial.
Intervention conditions — Provide at least two treatments, doses, or treatment/control states to compare. It is required contrast. Counterfactual: One uninterrupted exposure cannot identify a within-person comparative effect.
Repeated periods — Expose the same participant to conditions over time and allow replication. It is defining sequence. Counterfactual: A single pre/post contrast is more vulnerable to trend and chance.
Allocation and masking — Randomize order and conceal condition where feasible to control period and expectation bias. It is validity control. Counterfactual: A fixed open sequence can still be described but supports weaker causal inference.
Washout and carryover model — Separate effects across periods or explicitly model persistence. It is required validity condition. Counterfactual: Long irreversible or cumulative effects can invalidate crossover comparison.
Repeated outcome measure — Captures timely, meaningful response under each condition. It is required evidence. Counterfactual: An unstable or delayed measure can obscure the within-person effect.

What It Is Not¶

An N-of-1 trial is not any anecdote involving one patient.
It is not informal trial-and-error without prespecified conditions, outcomes, and comparison periods.
Self-tracking is observational unless interventions are prospectively assigned under a trial design.
One participant does not excuse consent, safety monitoring, registration, protocol discipline, or appropriate oversight.
Closest near-miss. A single-case experimental design is the broader family; a clinical N-of-1 trial usually centers a planned treatment crossover for one patient.

Scope of Application¶

Chronic stable conditions. Repeatedly measurable symptoms can be compared across reversible treatment periods.
Individual treatment selection. The participant's comparative benefit and harms can inform a shared clinical decision.
Rare or heterogeneous conditions. Within-person evidence can complement sparse group evidence when crossover assumptions hold.
Series of N-of-1 trials. Several individual experiments can be prospectively aggregated without erasing participant-specific effects.

Clarity¶

A report should state the participant, treatments, period length, randomization, masking, run-in, washout, outcome timing, carryover model, analysis, stopping rule, adverse events, and missing data. AB or ABA notation alone does not establish a rigorous trial. The design estimates what happened under specified periods; irreversible interventions, progressive disease, and long delayed effects may make crossover invalid.

Manages Complexity¶

Repeated crossover uses the participant as their own control, reducing stable between-person variation and directly targeting personal response. Time remains a confounder: trends, period effects, anticipation, adherence, and residual treatment can mimic a difference. Replication, randomization, washout, and time-series analysis manage those sources only when their assumptions are credible.

Abstract Reasoning¶

Define the individualized decision and treatments worth comparing.
Check reversibility, onset, washout, outcome sensitivity, and condition stability.
Prespecify periods, randomization, masking, measures, analysis, stopping, and safety rules.
Collect outcomes and adherence consistently through every period.
Estimate the within-person contrast with period, trend, and carryover effects represented.
Limit conclusions to the participant unless a planned series supports broader inference.

Knowledge Transfer¶

The design transfers across clinical questions when repeated assigned exposure is ethical, effects are reversible, and outcomes are timely. Personal productivity experiments may share the crossover structure but are not clinical trials without the health intervention, ethics, and oversight context. Group crossover trials use related logic across several participants but have different estimands.

Examples¶

Canonical¶

A participant completes randomized blinded AB/BA treatment pairs, separated by adequate washout, while recording the same symptom outcome each period under a prespecified analysis.

Mapped back: bias control → blinding and washout; conditions → A and B; outcome → repeated measure; participant → one; sequence → randomized repeated pairs.

Applied / In Practice¶

Trying one therapy, feeling better, and continuing it without planned reversal, comparator, repeated measurement, or carryover assessment is clinical trial-and-error rather than a rigorous N-of-1 trial.

Mapped back: classification → informal trial; comparison → absent; exposure → one; replication → absent.

Structural Tensions¶

T1 — Individual Relevance versus Generalizability. Within-person replication targets one patient's comparative response, while population claims require a series and hierarchical analysis.

Diagnostic: Is the conclusion limited to the participant or improperly generalized?

T2 — Repeated Crossover versus Carryover And Disease Change. More periods improve replication only when treatment effects wash out and the condition remains sufficiently stable.

Diagnostic: Are period length, washout, and secular trend credible for these interventions?

Structural–Framed Character¶

N-of-1 Trial is mixed. Allocation, period structure, outcomes, and analysis are formal; treatment choice, clinically meaningful change, consent, and safety are biomedical and institutional. A sound design does not itself make an intervention suitable for a person.

Structural Core vs. Domain Accent¶

The skeleton is repeated within-unit experimental comparison. Clinical research supplies patient, treatment, control, washout, harms, consent, and therapeutic decision. Removing them yields a single-case experiment rather than a clinical N-of-1 trial.

This entry is a kind of Experimental Design.

Approved root. No reviewed parent entails this single-participant multi-period clinical crossover design.
Related — experiment, crossover, randomization, and single-case design. These locate the method without collapsing its clinical identity.

Relationships to Other Abstractions¶

Current abstraction N-of-1 Trial Domain-specific

Parents (1) — more general patterns this builds on

N-of-1 Trial is a kind of Experimental Design Prime

An N-of-1 Trial is an Experimental Design that deliberately assigns comparative treatment conditions across planned periods within one participant.

Hierarchy paths (2) — routes to 1 parentless root

N-of-1 Trial → Experimental Design → Control Sample → Comparison → Self Checking

Show alternative path (1)

Neighborhood in Abstraction Space¶

N-of-1 Trial sits in a crowded region of the domain-specific corpus (38^th percentile for distinctiveness): several abstractions share nearly its structure, so a description that fits it tends to fit its neighbors too.

Family — Developmental & Clinical Mechanism Hypotheses (13 abstractions)

Nearest neighbors

Computed from structural-signature embeddings · 2026-10-08

Not to Be Confused With¶

Case report. Tell: Describes clinical events without a prospective repeated treatment comparison.
Single-case experimental design. Tell: Is the broader family spanning behavioral and other intervention designs.
Personal self-experiment. Tell: May lack randomization, masking, oversight, and a clinical protocol.
Group crossover trial. Tell: Estimates treatment effects across multiple participants rather than centering one participant's response.

References¶

Frozen Wikipedia discovery revision: https://en.wikipedia.org/wiki/N-of-1_trial (revision 1360711591).
Preserved source candidate: https://effectivehealthcare.ahrq.gov/products/n-1-trials/research-2014-4#toc-1
Preserved source candidate: https://link.springer.com/content/pdf/10.1007/978-94-017-7200-6.pdf
Preserved source candidate: http://iospress.metapress.com/content/t51wg3207328hv38/?genre=article&issn=1387-2877&volume=21&issue=3&spage=967
Preserved source candidate: https://archive.today/20130923221601/http://iospress.metapress.com/content/t51wg3207328hv38/?genre=article&issn=1387-2877&volume=21&issue=3&spage=967
Preserved source candidate: https://www.nof1sced.org/

The frozen Wikipedia revision is discovery provenance. The retained source set was reviewed for identity, formal or operational relation, and scope. The encyclopedia's structural synthesis is bounded to those claims; a thin authority surface is recorded as a nonblocking source-strengthening repair rather than concealed. - CENT 2015 Statement — CONSORT extension for reporting N-of-1 trials. - CENT 2015 Explanation and Elaboration — definitions and reporting rationale.